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Background: The combined effect of the metabolic syndrome (MS) risk factors on bone health has led to controversial
results and it is still not clear whether this effect is protective or detrimental. The study aimed to examine the association
between MS and bone mineral density (BMD), osteoporosis, and vertebral fractures (VFs) among ambulatory older
postmenopausal women.
Methods: 270 post-menopausal women with a mean age of 61.0 years ± 7.8 (50 to 90) with no prior known diagnosis
of osteoporosis were recruited. BMD and Lateral vertebral fracture assessment (VFA) images were obtained using a GE
Healthcare Lunar Prodigy densitometer. VFs were defined using a combination of Genant semiquantitative approach
and morphometry.
Results: The MS as defined by the NCEP-ATP III was present in 62 women (23.0%). According to the WHO classification,
82 had osteoporosis at any site (30.4%). VFs were identified in 116 (43.0%): 80 (29.6%) had grade 1 and 36 (13.3%) had
grade 2 or 3. Women with MS had a significantly higher BMD and lower prevalence of osteoporosis (17.7% vs. 34.1%)
than those without MS. No significant statistical difference was noted in prevalence of VFs (14.5 vs. 13.0%). There were
significantly less women with MS among the group of osteoporotic women (13% vs. 27%; p = 0.018). Conditional
regression binary analysis assessing the presence of osteoporosis as the dependent variable showed that women
with a MS had a significant 71% decrease in the odds of being osteoporotic by BMD compared with women who had
not MS accounting for age, BMI, number of parities and years since menopause.
Conclusion: Women with MS had higher BMD at the hip and spine, suggesting a protective effect of MS on bone.
However, the prevalence of VFs was similar between women with or without MS.
Keywords: Metabolic syndrome, Vertebral fracture assessment (VFA), Dual-energy X-ray absorptiometry (DXA),
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Metabolic syndrome (MS) is a clinical condition com-
posed of anthropometric, physiologic, and biochemical
abnormalities predisposing affected individuals to the
development of type 2 diabetes and cardiovascular dis-
ease. Rather than total adiposity, the core clinical com-
ponent of the syndrome is visceral and/or ectopic fat
(i.e., fat in organs not designed for fat storage), whereas
the principal metabolic abnormality is insulin resist-
ance [1]. The major characteristics of this syndrome in-
clude abdominal obesity, lipid abnormalities (high serum
triglyceride and/or low HDL cholesterol), hypertension,* Correspondence: aelmaghraoui@gmail.com
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article, unless otherwise stated.and hyperglycemia. In 2001, the National Cholesterol
Education Program-Adult Treatment Panel III (NCEP-
ATP III) [2] definition required the presence of at least 3
of the components mentioned above.
The association between each of these risk factors and
osteoporosis, a major cause of morbidity and mortality
in old age, has been extensively studied, with conflicting
results [3-10]. While some studies indicate a possible
protective effect of obesity or diabetes on fracture risk,
increased fracture risk among diabetics, patients with
high blood pressure or patients with high levels of chol-
esterol and/or triglycerides has been reported in some
but not all studies. The combined effect of the MS risk
factors on bone health has also led to controversial re-
sults. Therefore, it is still not clear whether this effect isentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tures in MS stands out from the studies undertaken up
to now. The concept that MS patients may suffer from
fewer fractures than controls seems logical since BMD is
often higher. Epidemiological studies, however, are not
conclusive. Most do not show differences in the inci-
dence of fractures between patients and controls, but re-
sults in either direction have also been reported [11,12].
Based on these conflicting results, and the high preva-
lence of osteoporosis, VFs and MS in the aging Moroccan
population [13,14], we conducted a cross-sectional study
to examine the association between MS and BMD, osteo-




A total of 270 caucasian postmenopausal women (age
range: 50–90 yr) living in the Rabat area participated in
the present study. Women were recruited through ad-
vertisements and “word of mouth” from june 2012 to
march 2013. Original inclusion criteria were age > 50,
menopause > 1 year and no previous osteoporotic frac-
ture or known diagnosis of osteoporosis. Women with
liver or renal disease, endocrine or metabolic abnormal-
ities, and receiving medicine known to influence bone
mineralization, such as corticosteroids, heparin, anticon-
vulsants, vitamin D, bisphosphonates, were excluded.
Our institutional review board (Comité d’éthique et de
recherche de l’hôpital Militaire Mohammed V) approved
this study. The procedures of the study were in accord-
ance with the Declaration of Helsinki, and local ethics
committee approval was obtained for the study (Comité
d’éthique de la Faculté de Médecine et de Pharmacie de
Rabat). All the participants gave an informed and written
consent. Each subject completed a standardized ques-
tionnaire designed to document putative risk factors of
osteoporosis. The questionnaire collected information
on current medication use, history of peripheral trau-
matic fractures, smoking habits, and level of physical ac-
tivity in leisure time, along with calcium consumption
and the use of vitamins and medications. Height and
weight were measured in light indoor clothes without
shoes. Body mass index (BMI)] was calculated by divid-
ing weight in kilograms by height in meters squared.
Waist was measured in centimeters at the bending point
using a flexible tape measure, with the participant wearing
single-thickness clothing and standing in an erect position
with feet together. Although this is not a population-
based cohort, care was taken to ensure representativeness
of the general population with a particular regard to the
inclusion of a wide range of age categories, body sizes and
activities. We did not exclude individuals using inhalation
steroids or with certain lifestyle habits such as heavysmoking, being sedentary, being athletic, or having a high
or low calcium intake, which are examples of voluntary
factors that may have some impact on bone metabolism.
The women were asked whether they usually drank milk
or alcohol; if they ate cheese or yogurt; if they did gymnas-
tics or jogging/walking and if they smoked tobacco. If the
answer was positive, they were asked to quantify their
average current consumption (evaluated on the 7 day
prior to the interview) of milk or yogurt (mL/day), cheese
(g/day) and wine and/or spirits (mL/day). Tobacco smoking
was quantified as average number of cigarettes (smoked/
day) multiplied by the number of years of smoking, gym-
nastics as min/week, or jogging/walking as min/day. Finally,
patients were categorized as never smokers, ex-smokers
and current smokers; high, normal and low calcium intake
(more than 1500 mg/day, between 800 and 1500 day − 1
and below 800 mg/day, respectively); high, moderate and
low physical activity (more than 3, 2–3 and below 1 hour/
week, respectively).
Bone mineral density (BMD) measurement
BMD was determined by a Lunar Prodigy Vision DXA
system (Lunar Corp., Madison, WI). The DXA scans were
obtained by standard procedures supplied by the manu-
facturer for scanning and analysis. All BMD measure-
ments were carried out by 2 experienced technicians.
Daily quality control was carried out by measurement of a
Lunar phantom. At the time of the study, phantom mea-
surements showed stable results. The phantom precision
expressed as the coefficient of variation was 0.08%. More-
over, reproducibility has been assessed in clinical practice
and showed a smallest detectable difference of 0.04 g/cm2
(spine) and 0.02 (hips) [15,16]. Patient BMD was mea-
sured at the lumbar spine (anteroposterior projection at
L1-L4) and at the femurs (i.e., femoral neck, trochanter,
and total hip). Using the Moroccan female normative data
[17], the World Health Organization (WHO) classification
system was applied, defining osteoporosis as T-score ≤ −2.5
and osteopenia as −2.5 < T-score < −1. Study participants
were categorized by the lowest T-score of the L1–4 lumbar
spine, femur neck, or total femur.
Vertebral fracture assessment
VFs was classified using a combination of Genant [18]
semiquantitative (SQ) approach and morphometry in
the following manner: each VFA image was inspected
visually by two trained clinicians (IG and AM) to decide
whether it contained a fracture in any of the visualized
vertebrae and assigned by consensus a grade based on
Genant SQ scale, where grade 1 (mild) fracture is a reduc-
tion in vertebral height of 20-25%, grade 2 (moderate) a re-
duction of 26-40%, and grade 3 (severe) a reduction of over
40%. In case of doubt regarding fracture grade, the verte-
brae in question was measured using built-in morphometry.
Table 1 Descriptive characteristics of the study
population (n = 270)
Range
Age (yrs): mean (SD) 61.0 (7.8) 50-90
Weight (kg): mean (SD) 75.5 (11.7) 45 – 106
Height (m): mean (SD) 1.55 (0.05) 1.35-1.79
BMI (kg/m2): mean (SD) 32.3 (6.5) 19-54
Years of menopause: mean (SD) 11.3 (8.1) 1-40
Number of pregnancies: mean (SD) 5.2 (2.4) 0-13
History of peripheral fractures: n (%) 69 (25.6)
Low physical activity: n (%) 179 (66.3)
Low calcium intake: n (%) 127 (47.0)
Diabetes: n (%) 79 (29.3)
Hypertension: n (%) 94 (34.8)
Dyslipidemia: n (%) 66 (24.4)
Waist circumference (cm): mean (SD) 103 .8 (10.7) 64-134
Hip circumference (cm): mean (SD) 113.1 (12.9) 58-232
Total body fat mass (%): mean (SD) 47.4 (4.9) 31.0 -56.2
Metabolic syndrome: n (%) 62 (23.0)
Lumbar spine BMD: mean (SD) 0.98 (0.17) 0.62 -1.94
Femoral neck BMD: mean (SD) 0.85 (0.14) 0.09 -1.8
Total hip BMD: mean (SD) 0.92 (0.12) 0.59 - 1.3
Lumbar spine T-SCORE: mean (SD) −1.45 (1.3) −4.5 - 2.8
Femoral neck T-SCORE: mean (SD) −1.42 (1.01) −3.7 - 1.2
Total hip T-SCORE: mean (SD) −0.85 (1.04) −3.6 - 2.3
Osteoporosis (any site): n (%) 82 (30.4)
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Positioning of the six morphometry points was modified
by one of the two clinicians only when the software failed
to correctly recognize vertebral heights. The intra-rater
reproducibility of this method was evaluated using the
kappa score to 0.90 (p < 0.0001). Subjects with no frac-
tures were included in the non-fracture group, whereas
those with grade 1 or higher fractures were included in
the fracture group. However, as many studies rarely report
mild deformities as “fractures”, and to realize comparisons
with the literature, we distinguished the group of women
with grade 1 fractures from the grade 2/3 fracture group.
The spinal deformity index (SDI), as described by Kerkeni
et al. [19], was then calculated by summing in each patient
the grade of each vertebra from T4 to L4. In theory, the
SDI value can vary between 0 (no fracture) and 39 (all the
assessed vertebrae are grade 3).
Metabolic syndrome
The prevalence of MS and its components were defined
by NCEP-ATP III criteria [2]. Participants were classified
as having the MS if any three of the following were
present: abdominal obesity (waist circumference greater
than 88 cm), triglycerides of 150 mg/dL (1.7 mmol/L) or
greater, HDL cholesterol levels less than 50 mg/dL
(1.29 mmol/L), fasting glucose of 110 mg/dL (6.1 mmol/L)
or greater, or blood pressure of 130/85 mmHg or greater.
Participants with documented use of antihypertensive
medication were categorized as meeting the blood pres-
sure criteria. Diabetes was defined by the American
Diabetes Association 1998 guidelines [20] (fasting plasma
glucose equal or greater than 126 mg/dL or 2-h plasma
glucose in 75 g oral glucose tolerance test equal or greater
than 200 mg/dL).
Statistical analysis
Results are presented as means (SD) for continuous vari-
ables and as frequencies for categorical variables. To com-
pare patients with and without MS and patients with or
without osteoporosis, chi-square test and Student t-test
were used. To compare patients with and without VFs,
chi-square test and analysis of variance ANOVA were
used.Potential risk factors for osteoporosis were finally en-
tered to a stepwise conditional binary logistic regression
analysis and the resulted odds ratios with 95% confidence
intervals were reported. The level for significance was




In this series of 270 women, the mean ± SD (range) age,
weight and BMI were 61.0 ± 7.8 (50 to 90) years, 75.5 ±
11.7 (45 to 106) Kg and 32.3 ± 6.5 (19.1 to 54.8) kg/m2,respectively (Table 1). Only 4 women (0.4%) were current
smokers. Sixty nine (25.6%) women reported a history of
traumatic peripheral fracture before the age of 50. Dia-
betes was present in 79 women (29.3%), hypertension in
94 (34.8%) and dyslipidemia (hypercholesterolemia and/or
hypertriglyceridemia) in 66 (24.4%). The MS as defined by
the NCEP-ATP IIIwas present in 62 women (23.0%).
Bone mineral density
The mean BMD was 0.98 (0.17) g/cm2 at the lumbar spine,
0.85 (0.14) g/cm2 at the femoral neck and 0.92 (0.12) g/cm2
at the total hip. The mean T-scores were −1.45 (1.3), −1.42
(1.01) and −0.85 (1.04) respectively. According to the
WHO classification, 82women had osteoporosis at any
site (30.4%).
Vertebral visualization and fracture identification on VFA
In these 270 women, 85.7% of vertebrae from T4–L4 and
96.2% from T8–L4 were adequately visualized on VFA.
The percentage of vertebrae not visualized at T4, T5, and
T6 levels was 51.9%, 40.7, and 26.7% respectively. VFs
were identified in 116 (43.0%): 80 (29.6%) had grade 1
and 36 (13.3%) had grade 2 or 3. Among the latter group,
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common in the mid-thoracic spine and at the thora-
columbar junction (Figure 1). The mean SDI was 1.20 ±
2.2 (0–12).
Data analysis
Comparison between patients with and without MS
(Table 2) showed that those with MS were older, had more
pregnancies and longer period since menopause. They
had a significantly higher BMD (lumbar spine, femoral
neck and total hip) and lower prevalence of osteoporosis
as the defined by the WHO criteria (17.7% vs. 34.1%; p =
0.029). No significant statistical difference was noted in
prevalence of VFs (14.5 vs. 13.0%; p = 0.672).
Comparison between patients with and without osteo-
porosis (T-score below −2.5 in any of the lumbar spine,
femoral neck or total hip) showed that those with osteo-
porosis were older, had lesser weight, height, BMI, and
total body fat percentage and had longer period since
menopause (Table 3). There were significantly less women
with MS among the group of osteoporotic women (13%
vs. 27%; p = 0.018).
Comparison between patients without VFs and pa-
tients with VFs grade 1 and grade 2/3 (Table 4) showed
that women with VFs were older, have a longer period
since menopause, were more likely to have history of
traumatic peripheral fracture and had a lower BMD at
the lumbar spine, femoral neck and total hip. Prevalence
of MS was similar between the three groups.
Conditional regression binary analysis assessing the
presence of osteoporosis as the dependent variable showed
that women with a MS had a significant 71% decrease in
the odds of being osteoporotic by BMD compared with
women who had not MS accounting for age, BMI, num-
ber of parities and years since menopause. The pre-
dictive variables significantly associated to the osteoporotic
status were the presence of MS, BMI, and number of par-
ities (Table 5).Figure 1 Vertebral fractures distribution in our study population.Discussion
In this series of postmenopausal women over 50, MS
was significantly and independently associated to higher
BMD and lower prevalence of osteoporosis. However,
prevalence of VFA-detected asymptomatic VFs was iden-
tical in participants with or without MS.
In the aging population, osteoporosis is an important
public health problem worldwide due to its high morbidity
and mortality [21]. Also, MS is another very common med-
ical problem of epidemic importance, and the number of
patients with MS is rapidly increasing in industrialized
countries where Western life-style is prevalent.
The prevalence of MS in our study population (23%)
was similar to the reported prevalence in adult Caucasians
in the United States (20 to 25%) [22], and in Russia [23]
(23.1%). Studies of general population demonstrated that
the overall prevalence of MS in European countries in
women varies from 2.1% in France [24], 14.2% in Finland
[25] to 20.9% in Poland [26]. Moreover, it has been shown
that the prevalence of MS increases with age and can
reach up to 64.4% for women in the 80–89 years of age
group [27].
The pathogenesis of MS is multifactorial and progres-
sive. The risk factors of MS are of metabolic origin and
consist of abdominal adipose tissue accumulation, athero-
genic dyslipidemia, elevated plasma glucose, elevated
blood pressure, and a prothrombotic and proinflammatory
state. The major risk factors are abdominal obesity and in-
sulin resistance accompanied by increased risk for CVD
and type 2 diabetes. Furthermore, aging, physical inactiv-
ity, endocrine, and genetic factors exacerbate the MS [28].
Accumulating evidence suggests that individual compo-
nents of MS such as hypertension, increased triglycerides,
and reduced high-density lipoprotein cholesterol are also
risk factors for low BMD while other components such as
obesity are associated to high BMD.
Many recent publications studied the relation of MS
and osteoporosis [29,30]. In the Rancho Bernardo Study
[31], after adjusting for BMI, MS was related to lower
BMD. Furthermore, the incidence of osteoporotic non-
vertebral fractures was elevated in subjects with MS. In a
US population-based study, subjects with MS had an in-
creased femoral neck BMD compared with controls without
the syndrome [32]. In the same study, initially unadjusted
femoral neck BMD was reduced among persons with MS,
but after adjustment for age, gender, and other covariates,
it was higher in subjects with MS than in control groups.
Moreover, in multivariate linear regression models for
each component of MS, femoral neck BMD was sig-
nificantly higher in subgroups of people with abdom-
inal obesity and diabetes. Hwang et al. [33] reported in
2475 Korean women (21% with MS) that, after adjustment
for all covariates, mean vertebral BMD was significantly
lower in women with MS. Ahmed and colleagues [34]
Table 2 Comparison between patients with and without metabolic syndrome
Metabolic syndrome (N = 62) Absence of metabolic syndrome (N = 208) p
Age (yrs): mean (SD) 63.3 (8.4) 60.1 (7.5) 0.013
Weight (Kg): mean (SD) 79.7 (10.2) 74.2 (11.7) 0.001
Height (m): mean (SD) 1.55 (0.05) 1.55 (0.06) NS
BMI (Kg/m2): mean (SD) 33.2 (6.0) 32.0 (6.6) NS
Diabetes: n (%) 49 (79.0) 30 (14.4) 0.0001
Hypertension: n (%) 56 (90.3) 38 (18.3) 0.0001
Dyslipidemia: n (%) 40 (64.5) 26 (12.5) 0.0001
Low physical activity: mean (SD) 39 (62.9) 140 (67.3) NS
Low calcium intake: mean (SD) 30 (48.4) 97 (46.6) NS
Number of pregnancies: n (%) 6.0 (2.7) 5.0 (2.3) 0.008
Years since menopause (yrs): mean (SD) 12.6 (8.5) 11.1 (7.9) 0.002
Waist circumference (cm): mean (SD) 107.1 (9.7) 102.7 (10.8) 0.002
Hip circumference (cm): mean (SD) 117.1 (17.7) 111.7 (11.8) 0.03
History of traumatic fractures: n (%) 20 (32.3) 49 (23.6) NS
Lumbar spine (g/cm2): mean (SD) 1.025 (0.15) 0.977 (0.17) 0.038
Lumbar spine T-score: mean (SD) −1.08 (1.2) −1.57 (1.3) 0.001
Total hip BMD (g/cm2): mean (SD) 0.972 (0.13) 0.908 (0.12) 0.003
Total hip T-score: mean (SD) −0.4 (1.0) −0.9 (1.0) 0.001
Femoral neck BMD (g/cm2): mean (SD) 0.887 (0.18) 0.843 (0.12) 0.094
Femoral neck T-score: mean (SD) −1.2 (1.0) −1.4 (1.0) 0.087
Osteoporosis (T-score below −2.5 any site): n (%) 11 (17.7) 71 (34.1) 0.029
Vertebral fractures grade 2–3: n (%) 9 (14.5) 27 (13.0) NS
Spinal deformity index (SDI): mean (SD) 0.95 (1.6) 1.29 (2.4) NS
Table 3 Comparison between patients with and without osteoporosis
Osteoporosis (N = 82) Absence of osteoporosis (N = 188) p
Age (yrs): mean (SD) 64.0 (8.4) 59.6 (7.5) <0.0001
Weight (Kg): mean (SD) 70.8 (13.2) 77.5 (10.7) <0.0001
Height (m): mean (SD) 1.53 (0.05) 1.56 (0.06) <0.0001
BMI (Kg/m2): mean (SD) 31.0 (6.3) 33.1 (6.7) 0.017
Obesity (BMI > 30 Kg/m2): n (%) 42 (51.2) 107 (56.9) NS
Diabetes: n (%) 18 (22.0) 61 (32.4) NS
Hypertension: n (%) 24 (29.3) 70 (37.2) NS
Dyslipidemia: n (%) 11 (13.4) 55 (29.3) 0.003
Metabolic syndrome: n (%) 11 (13.4) 51 (27.1) 0.018
Low physical activity: mean (SD) 60 (73.2) 119 (63.3) NS
Low calcium intake: mean (SD) 38 (46.3) 89 (47.3) NS
Number of pregnancies: n (%) 5.8 (2.7) 5.0 (2.3) 0.016
Years since menopause (yrs): mean (SD) 15.0 (8.9) 9.9 (7.2) <0.0001
Waist circumference (cm): mean (SD) 103.9 (9.7) 103.6 (10.8) NS
Hip circumference (cm): mean (SD) 111.1 (17.7) 113.7 (11.8) NS
Percentage of body fat: mean (SD) 46.1 (6.1) 47.9 (4.0) 0.016
History of traumatic fractures: n (%) 20 (24.4) 49 (26.1) NS
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Table 4 Comparison between patients with and without vertebral fractures
Absence of VFs (N = 154) VFs grade 1 (N = 80) VFs grade 2–3 (N = 36) p
Age (yrs): mean (SD) 59.6 (7.36) 62.1 (8.4) 64.3 (8.07) <0.001
Weight (Kg): mean (SD) 75.9 (11.0) 74.8 (12.7) 75.3 (11.7) NS
Height (m): mean (SD) 1.55 (0.05) 1.56 (0.05) 1.54 (0.06) NS
BMI (Kg/m2): mean (SD) 32.4 (6.5) 32.0 (6.6) 32.6 (6.3) NS
History of traumatic fractures: n (%) 33 (21.4) 22 (27.5) 14 (38.9) 0.03
Low physical activity: n (%) 102 (66.2) 51 (63.8) 26 (72.2) NS
Low calcium intake: n (%) 73 (47.4) 36 (45.0) 18 (50.0) NS
Years since menopause (yrs): mean (SD) 10.1 (7.6) 13.1 (8.4) 13.9 (8.4) 0.003
Number of pregnancies: n (%) 5.0 (2.3) 5.7 (2.4) 5.5 (3.0) NS
Diabetes: n (%) 54 (35.1) 16 (20.0) 9 (25.0) NS
Hypertension: n (%) 51 (33.1) 26 (32.5) 17 (47.2) NS
Dyslipidemia: n (%) 36 (23.4) 22 (27.5) 7 (19.4) NS
Metabolic syndrome: n (%) 34 (22.1) 19 (23.8) 9 (25.0) NS
Waist circumference (cm): mean (SD) 103.7 (10.4) 103.9 (10.6) 103.6 (12.3) NS
Hip circumference (cm): mean (SD) 113.6 (14.3) 111.9 (10.4) 113.0 (10.7) NS
Lumbar spine BMD (g/cm2): mean (SD) 1.011 (0.16) 0.966 (0.19) 0.936 (0.12) 0.029
Lumbar spine T-score: mean (SD) −1.30 (1.1) −1.56 (1.6) −1.83 (1.0) NS
Total hip BMD (g/cm2): mean (SD) 0.943 (0.11) 0.905 (0.15) 0.881 (0.12) 0.013
Total hip T-score: mean (SD) −0.69 (0.9) −0.99 (1.2) −1.22 (1.0) 0.012
Femoral neck BMD (g/cm2): mean (SD) 0.869 (0.13) 0.831 (0.13) 0.834 (0.19) NS
Femoral neck T-score: mean (SD) −1.25 (0.9) −1.53 (1.1) −1.83 (0.8) 0.005
Osteoporosis (T-score below −2.5 any site): n (%) 44 (24.0) 32 (40.0) 14 (38.9) 0.006
BMI body mass index; BMD bone mineral density; VFs vertebral fractures.
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HDL, triglycerides and hypertension) and risk of non-
vertebral fractures in 12,780 men and 14,211 women aged
25–98 years (mean = 47 years for both sexes) from the
Tromso study, and concluded that increasing burden of
MS components protects against non-vertebral fractures.
However, participants in this study were young (mean =
47 years) and fractures were not limited to low trauma
osteoporotic fractures. Traumatic fractures are more likely
to occur in younger participants, and may have a different
pathophysiology than osteoporotic fractures. In a recentTable 5 Adjusted odds ratios from logistic regression
with osteoporosis as the dependant variable
OR IC 95% p
Metabolic syndrome 0.291 0.130 – 0.651 0.003
Age 1.032 0.977 – 1.091 0.262
Body mass index (BMI) 0.941 0.896 – 0.987 0.013
Years since menopause 1.056 1.000 – 1.115 0.05
Number of pregnancies 1.145 1.008 – 1.290 0.032
Percentage of body fat 0.971 0.910 – 1.037 0.385
Odds ratios are adjusted for age, BMI, years since menopause and number
of pregnancies.cross-sectional publication of 2265 women aged over 20
(with prevalence of the MS 5.5% in the premenopausal
women and 13.5% in the postmenopausal), Jeon et al. [35]
found that women with MS had a lower BMD at the
lumbar spine and femoral neck. They also found that the
predictive variables for femoral neck BMD were CRP and
diastolic blood pressure.
Several factors may explain the controversial results
making it difficult to assess whether or not MS and osteo-
porosis are associated. Although the vast majority of stud-
ies addressing bone metabolism in patients with MS have
adopted the NCEP-ATPIII criteria, the studied popula-
tions are different. Moreover, a certain degree of hetero-
geneity in their profile is inherent to these criteria. In fact,
the diagnosis of MS is made when just three out of
five NCEP-ATPIII criteria are satisfied. Consequently,
even this definition entails a degree of heterogeneity, as
any three or more criteria may be met by each patient. An
additional problem is that the confounders used in these
studies’ adjustments do not always coincide. This com-
ment is particularly relevant regarding BMI and its related
variables (waist perimeter, body weight). Since adjusting
for body weight or BMI is, in general, a common proced-
ure in epidemiological studies, results of MS studies are
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ment distorts the clinical profile of MS, which by def-
inition includes high body weight, waist perimeter or
BMI. Hernandez et al. claimed that when adjusting for
these, the clinical sense of MS just disappears, or is at least
essentially modified [11].
It has been suggested that higher BMD with MS is
largely determined by abdominal obesity, and protective
effects of fat mass may promote bone formation via high
mechanical loading [36], high circulating insulin levels,
and factors that are co-secreted with insulin [32]. It is
well demonstrated that osteoporosis is linked to inflam-
mation. Previous studies suggest that subjects with high
insulin resistance show more inflammation than subjects
with low insulin resistance state [37-39] and some stud-
ies suggest that this low state of chronic inflammation
may impact bone health [40,41]. Thus the observed con-
flicting results may be due to the counteracting of a nega-
tive effect of low-grade inflammation associated with MS
and the protective effect of adiposity [5]. This apparent
paradox may be explained by the fact that, at a given level
of BMD, MS patients present lower bone quality by means
of various mechanisms, including hyperinsulinemia, de-
position of advanced glycosylation endproducts (AGEs) in
collagen, reduced serum levels of IGF-1, hypercalciuria,
renal failure, microangiopathy and inflammation.
Our study has strengths and limitations. The assessment
of BMD and fractures was carefully conducted using
standard procedures of acquisition, and standard reading
of all VFA scans. All the morphometric assessments were
made by two experienced investigators after training ses-
sions and after a previous global visualization. The preva-
lence of obesity and MS was high in our study (64% and
23% respectively) but reflects what is observed in the
aging female Moroccan population.The main limitation
lies in the procedures used to select subjects, who were all
volunteers and ambulatory. The Rabat population may
not be adequately representative of the whole Moroccan
population. However, since the population living in the
area of Rabat is a balanced mixture of the various regions
constitutive of the country, we believe the impact on
prevalence of VFs or MS estimate is limited. Another limi-
tation is the lack of information about some biological var-
iables that may influence BMD and/or VFs prevalence
such as serum 25(OH) vitamin D3 or CRP levels.
Conclusion
Our study showed that even women with the MS had
higher BMD at the hip and spine, suggesting a protective
effect of MS on bone, the prevalence of VFs was similar
among women with or without MS.Competing interests
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